Posttraumatic stress disorder: An integrated overview of the neurobiological rationale for pharmacology.
Lists
Only you see this
Abstract
Thirty years of research on the biology of posttraumatic stress disorder now provides a foundation for hypotheses related to the mechanisms underlying the pharmacotherapy of this disorder. Only two medications, sertraline and paroxetine, are approved by the U.S. Food and Drug Administration for the treatment of PTSD. While these medications are somewhat effective, other treatment mechanisms must be explored to address the unmet need for effective treatment. This article provides a concise summary of advances in our understanding of the neurobiology of PTSD that suggest novel approaches to pharmacotherapy.
BibTeX
@inproceedings{kelmendi2017posttraumatic,
author = {Benjamin Kelmendi and Thomas G. Adams and Steven M. Southwick and Chadi G. Abdallah and John H. Krystal},
title = {{Posttraumatic stress disorder: An integrated overview of the neurobiological rationale for pharmacology.}},
booktitle = {Clinical},
year = {2017},
doi = {10.1111/cpsp.12202},
}Loading related content...